



Altimune to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 26, 2025 at 7:30 AM EST

GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference. Details are as follows:

Conference: *Piper Sandler 37th Annual Healthcare Conference*

Date/Time: *Wednesday, December 3, 2025 at 2:30 p.m. ET*

The session will be webcast and can be accessed by visiting the [Events](#) section of the Altimune website.

About Altimune

Altimune is a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company's lead product candidate is pemvidutide, a glucagon/GLP-1 dual receptor agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimune, Inc. on [LinkedIn](#)

Follow @AltimuneInc on [X](#)

Investor Contact:

Lee Roth

Burns McClellan

Phone: 646-382-3403

lroth@burnsmc.com

Media Contact:

Savannah Valade

Real Chemistry

altimmune@realchemistry.com

This press release was published by a CLEAR® Verified individual.



Source: Altimune, Inc